CA
ENTX icon

Clearstead Advisors’s Entera Bio ENTX Stock Holding History

Clearstead Advisors’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500
Closed -$2K – 1271
2021
Q1 		$2K Buy
+500
New +$1.15K ﹤0.01% 958

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Clearstead Advisors's ENTX Position: Q2 2021 in Review

Clearstead Advisors sold out of Entera Bio (ENTX) in Q2 2021, closing a stake of 500 shares — an estimated $2K sold.

Clearstead Advisors first reported a position in ENTX in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 14 funds tracked by Wall St. Rank hold ENTX as of Q2 2021.

  • Clearstead Advisors reported no remaining Entera Bio position as of Q2 2021 after selling out during the quarter.
  • Clearstead Advisors sold 500 Entera Bio shares in Q2 2021, an estimated $2K.
  • Clearstead Advisors first reported a position in Entera Bio in Q1 2021 and held it in 1 quarter.
  • Clearstead Advisors's Entera Bio position peaked at $2K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Entera Bio as of Q2 2021.

Based on Clearstead Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.